---
title: "An integrative multiparametric approach stratifies putative distinct phenotypes of blast phase chronic myelomonocytic leukemia"
collection: publications
date: 2025-01-31
venue: 'Cell Reports Medicine'
paperurl: https://doi.org/10.1016/j.xcrm.2025.101933
keywords: CMML, Blast Phase, Secondary AML, MDS/MPN, Leukemic Transformation, Leukemia
---
<div style="text-align: center;">
  <img src="https://raw.githubusercontent.com/EspressoKris/Portfolio/master/images/GraphicalAbstracts/2025_CRM_Gurashi.jpg" alt="Graphical Abstract" style="width: 370px; height: 350px;">
</div>

### Publication link
[https://doi.org/10.1016/j.xcrm.2025.101933](https://doi.org/10.1016/j.xcrm.2025.101933)

### Code repository link
[https://github.com/EspressoKris/Manuscript__2024__CRM__BP-CMML_Stratification](https://github.com/EspressoKris/Manuscript__2024__CRM__BP-CMML_Stratification)

### Key findings
- Blast phase CMML is a molecularly and clinically distinct form of acute leukemia
- RNA-seq of BP-CMML blasts identifies novel disrupted gene networks and pathways
- Machine learning approach stratifies BP-CMML along a maturation spectrum
- BP-CMML subtypes exhibit distinct therapeutic vulnerabilities  

### Summary
Approximately 30% of patients with chronic myelomonocytic leukemia (CMML) undergo transformation to a chemo-refractory blastic phase (BP-CMML). Seeking novel therapeutic approaches, we profiled blast transcriptomes from 42 BP-CMMLs, observing extensive transcriptional heterogeneity and poor alignment to current acute myeloid leukemia (AML) classifications. BP-CMMLs display distinctive transcriptomic profiles, including enrichment for quiescence and variability in drug response signatures. Integrating clinical, immunophenotype, and transcriptome parameters, Random Forest unsupervised clustering distinguishes immature and mature subtypes characterized by differential expression of transcriptional modules, oncogenes, apoptotic regulators, and patterns of surface marker expression. Subtypes differ in predicted response to AML drugs, validated ex vivo in primary samples. Iteratively refined stratification resolves a classification structure comprising five subtypes along a maturation spectrum, predictive of response to novel agents including consistent patterns for receptor tyrosine kinase (RTK), cyclin-dependent kinase (CDK), mechanistic target of rapamycin (MTOR), and mitogen-activated protein kinase (MAPK) inhibitors. Finally, we generate a prototype decision tree to stratify BP-CMML with high specificity and sensitivity, requiring validation but with potential clinical applicability to guide personalized drug selection for improved outcomes.  

### Citation
> Gurashi, K., Wang, Y.-H., Amaral, F. M. R., Spence, K., Cant, R., Yao, C.-Y., Lin, C.-C., Wirth, C., Wedge, D. C., Montalban-Bravo, G., Colla, S., Tien, H.-F., Somervaille, T. C. P., Batta, K., & Wiseman, D. H. (2025). An integrative multiparametric approach stratifies putative distinct phenotypes of blast-phase chronic myelomonocytic leukemia. *Cell Reports Medicine, 6*(101933). https://doi.org/10.1016/j.xcrm.2025.101933

### Metrics
<div style="text-align: center;">
  <a href="https://plu.mx/plum/a/?doi=10.1371/j.xcrm.2025.101933" data-hide-print="true" class="plumx-details plum-bigben-theme" data-site="plum" data-hide-when-empty="true" data-no-link="true" data-pass-hidden-categories="true" data-hide-mentions="true" data-hide-socialmedia="false">An integrative multiparametric approach stratifies putative distinct phenotypes of blast-phase chronic myelomonocytic leukemia</a>
</div>